FDA lifts partial clinical hold on lacutamab clinical program Fatal case related to disease progression and unrelated to the treatment Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ”...

Sanofi to exercise one option to license a new ANKET ® program from Innate; After a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization...

Current CEO Mondher Mahjoubi to leave Innate Pharma to pursue an opportunity at a large pharmaceutical company Current Chairman of the Supervisory Board, former CEO and company co-founder Hervé...

SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under...

Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients. Virtual KOL event will be held on...

The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome which have been selected for oral...

Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome selected for oral presentation and preliminary data in Peripheral T Cell lymphoma to be displayed in a poster at ASH...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m...

Positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome selected for oral presentation Preliminary monotherapy...